A second-generation antibody-drug conjugate to treat HER2-positive breast cancer. Rassy E, Delaloge S. Lancet 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rassy E, Delaloge S. A second-generation antibody-drug conjugate to treat HER2-positive breast cancer. Lancet 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
PMID: 36495878